Subtype
Diffuse Glioma
CI-CAN-00002519Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002519Explore in graph →
Clinical trials
2,804 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05380349 | Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma | recruiting | Early Phase 1 | 10 | Swedish Medical CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06381570 | Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas(VICTORY) | recruiting | Early Phase 1 | 57 | Daniel MorgensternOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05432518 | Pilot Trial for Treatment of Recurrent Glioblastoma | recruiting | Early Phase 1 | 10 | AHS Cancer Control AlbertaOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05473923 | PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas | active not recruiting | Early Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06757153 | Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients | recruiting | Early Phase 1 | 15 | Zhongnan HospitalOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06396481 | Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma(CSAγδTBMG) | not yet recruiting | Early Phase 1 | 25 | Beijing Tiantan HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT03763396 | Azoles Targeting Recurrent High Grade Gliomas | not yet recruiting | Early Phase 1 | 30 | University Health Network, TorontoOTHER | 1 | Mar 8, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 16, 2025source: clinicaltrials